348 Studies Now Enrolling
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 Over 21 Days in Ambulatory Adult Patients With Type 1 and Type 2 Charcot- Marie-Tooth Disease
Safety and Efficacy of NMD670 in Adult Patients with Type 1 and Type 2 Charcot-Marie-Tooth Disease
| Sponsor: | NMD Pharma |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAV1960 |
| U.S. Govt. ID: | NCT06482437 |
| Contact: | Raisy Fayerman, CRC: 212-305-6035 / rf2632@cumc.columbia.edu |
Additional Study Information:
The study is enrolling subjects 18-70 year old. Diagnosis of CMT type 2 confirmed by genetic testing. 6-Minute Walk Test Total distance must be met without assistive devices such as AFOs (orthopedic) inserts are allowed) at screening. Receiving physical or occupational therapy or following a prescribed training regimen for more than 30 days prior to screening should continue their current treatment regimen throughout the study.
This study is closed
Do You Qualify?
| Do you currently use any daily assistive devices, such as Ankle-Foot Orthoses (AFOs)? | Yes | No |
| Have you had ankle surgery or any other limb-related procedures for CMT within the past 9 months? | Yes | No |
| Has your diagnosis of CMT Type 2 been confirmed through genetic testing? | Yes | No |
| If you qualify for the study, would you be able to spend 4-6 hours at the hospital each week? | Yes | No |
| Do you have a history of alcohol abuse or use of drugs such as cocaine, heroin, opiates, or marijuana? | Yes | No |